tbuckley/cabot-search huggingface dataset:
A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for <i>IDH2</i>-Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation
Authors: Amir T. Fathi, Shuli Li, Robert J. Soiffer, Mark Levis, Alice S. Mims, Steven M Devine, Zachariah Defilipp, Areej El-Jawahri, Steven L. McAfee, Thomas R. Spitzer, Matthew J Frigault, Bimalangshu R. Dey, Philip C. Amrein, Gabriela S. Hobbs, Andrew M. Brunner, Hanno R. Hock, Rupa Narayan, Laura W. Knight, Devon Kelley, AJ S. Bottoms, Jami L. Brown, Candice J. Del Rio, Julie E. Vanderklish, Colleen Danielson, Meredith L. Saylor, Chrisa L. Hunnewell, Lindsey H. Perry, Jonathan L. Wahl, Elayne Breton, Vincent T. Ho, Yi-Bin Chen
Journal: Blood (2020)
A Journey of Nanomotors for Targeted Cancer Therapy: Principles, Challenges, and a Critical Review of the State‐of‐the‐Art
Authors: Wei Wang, Chao Zhou
Journal: Advanced Healthcare Materials (2020)

Abstract A nanomotor is a miniaturized device that converts energy stored in the environment into mechanical motion. The last two decades have witnessed a surge of research interests in the biomedical applications of nanomotors, but little clinical translation. To accelerate this process, targeted cancer therapy is used as an example to describe a “survive, locate, operate, and terminate” (SLOT) mission of a nanomotor, where it must 1) survive in the unfriendly in vivo environment, 2) locate its target as well as be located by human operators, 3) carry out specific operations, and 4) terminate after the mission is completed. Along this journey, the challenges presented to a nanomotor, including to power, navigate, steer, target, release, control, image, and communicate are discussed, and how state‐of‐the‐art nanomotors meet or fall short of these requirements is critically reviewed. These discussions are then condensed into a table for easy reference. In particular, it is argued that chemically powered nanomotors are intrinsically ill‐positioned for targeted cancer therapy, while nanomotors powered by magnetic fields or ultrasound show more promises. Following this argument, a tentative nanomotor design is then presented in the end to conform to the SLOT guideline, and to inspire practical, functional nanorobots that are yet to come.
The IGLV3-21R110 Defines a Subset of Chronic Lymphocytic Leukemia with Intermediate Epigenetic Subtype and Poor Outcome
Authors: Ferran Nadeu, Romina Royo, Guillem Clot, Martí Duran-Ferrer, Alba Navarro, Silvia Martín, Junyan Lu, Thorsten Zenz, Tycho Baumann, Pedro Jares, Xose S Puente, Jose Ignacio Martin-Subero, Julio Delgado, Elias Campo
Journal: Blood (2020)
Isatuximab Short-Duration Fixed-Volume Infusion Plus Bortezomib (V) Lenalidomide (R) and Dexamethasone(d) Combined Therapy for Newly Diagnosed Multiple Myeloma (NDMM): Results from a Phase 1b Feasibility/Safety Study
Authors: Enrique M. Ocio, Aurore Perrot, Pierre Bories, Jesus F. San-Miguel, Igor W Blau, Lionel Karlin, Joaquin Martinez-Lopez, Wolfram Pönisch, Sara Bringhen, Fabio Ciceri, María-Victoria Mateos, Paula Rodriguez-Otero, Nadia Le Roux, Yvonne Dong, Thomas Fitzmaurice, Corina Oprea, Philippe Moreau
Journal: Blood (2020)
Abstract 489: Identification And <i>In-silico</i> Analysis Of Pathogenic Non-synonymous Snps Of Human Sos1 Protein In Noonan Syndrome
Authors: Vinoth Sigamani, SHEEJA RAJASINGH, Narasimman Gurusamy, Shivaani Kirankumar, Jayavardini Vasanthan, Rajasingh Johnson
Journal: Circulation Research (2020)

Introduction: Noonan syndrome is a genetic disorder (autosomal dominant) characterized by short stature, congenital heart disease, bleeding problems, developmental delays, and skeletal malformation. It is mainly caused by a single nucleotide alteration in four genes PTPN11, SOS1, RAF1, and KRAS . In this study, we computationally analyzed the SOS1 gene to identify the pathogenic non-synonymous single nucleotide polymorphisms (nsSNPs), which is known to cause Noonan syndrome. Hypothesis: We hypothesize that in-silico analysis of human SOS1 mutations in Noonan syndrome would be a promising predictor to study the post-translational modifications. Methods and Results: The variant information of SOS1 was collected from the dbSNP database and the literature review on Noonan syndrome. They were further analyzed by in-silico tools such as I-Mutant, iPTREE-STAB, and MutPred for their structural and functional properties. We found that 11 nsSNPs are more pathogenic for Noonan syndrome. The 3D comparative protein of 11 nsSNPs with its wild-type SOS1 was modeled by using I-Tasser and validated via ERRAT and RAMPAGE. The protein-protein interactions of SOS1, GATA4, TNNT2, and ACTN2 were analyzed using STRING, which showed that HRAS was intermediate between SOS1 and ACTN2 (Fig. 1) . Conclusion: This is the first in-silico study of the SOS1 variant with Noonan syndrome. We proposed that this 11 nsSNPs are the most pathogenic variant of SOS1 , which helps to screen the Noonan patient. Furthermore, our results are promising to study the gain/loss of post-translational modification (PTM) by mutation in cardiac genes and helps to explore the novel molecular pathways.$graphic_{DB5B0E7D-4DA6-4569-A16F-E05B2C9C4D2F}$$
Assessment of a deep-learning system for fracture detection in musculoskeletal radiographs
Authors: Rebecca M. Jones, Anuj Sharma, Robert Hotchkiss, John W. Sperling, Jackson Hamburger, Christian Ledig, Robert O’Toole, Michael Gardner, Srivas Venkatesh, Matthew M. Roberts, Romain Sauvestre, Max Shatkhin, Anant Gupta, Sumit Chopra, Manickam Kumaravel, Aaron Daluiski, Will Plogger, Jason Nascone, Hollis G. Potter, Robert V. Lindsey
Journal: npj Digital Medicine (2020)

Abstract Missed fractures are the most common diagnostic error in emergency departments and can lead to treatment delays and long-term disability. Here we show through a multi-site study that a deep-learning system can accurately identify fractures throughout the adult musculoskeletal system. This approach may have the potential to reduce future diagnostic errors in radiograph interpretation.
Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features
Authors: Jonathan A. Gutman, Amanda Winters, Maria L Amaya, Christine M. McMahon, Jeffrey Schowinsky, Diana Abbott, Andrew Hammes, Shanshan Pei, Brett M. Stevens, Craig T. Jordan, Clayton Smith, Daniel A. Pollyea
Journal: Blood (2020)
IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure
Authors: Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Ioanna Dialoupi, Foteini Theodorakakou, Maria Roussou, Evangelos Terpos, Efstathios Kastritis, Meletios A. Dimopoulos
Journal: Blood (2020)
Extending Dosing Intervals of Denosumab As a Maintenance Strategy in Multiple Myeloma: A Real-World Experience at a Large Academic Cancer Center
Authors: E. Bridget Kim, Yael N. Kahn, Andrew R. Branagan, Andrew J. Yee, Jill N. Burke, Cynthia C. Harrington, Emerentia Agyemang, Noopur S. Raje, Elizabeth K. O'Donnell
Journal: Blood (2020)
Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations
Authors: Massimiliano Bonifacio, Chiara Elena, Mariella D'Adda, Luigi Scaffidi, Mairi Pucci, Fiorenza Aprili, Jacqueline Ferrari, Alessandra Tucci, Fabio Stagno, Anna Rita Scortechini, Gianni Binotto, Mario Annunziata, Maria Cristina Miggiano, Isabella Capodanno, Sara Galimberti, Mario Tiribelli, Emilia Giugliano, Giovanni Caocci, Monica Crugnola, Paola Ronchi, Sabina Russo, Martina Tinelli, Agostino Tafuri, Monica Bocchia, Alessandra Malato, Mauro Krampera, Giuseppe Lippi, Massimo Breccia, Giuseppe Saglio, Antonella Gozzini
Journal: Blood (2020)
Immunoglobulin Superfamily Member 8 Is Indispensable for Myeloid Leukemia Via Wnt/β-Catenin Signaling Pathway
Authors: Koji Jimbo, Takaaki Konuma, Takahiro Ito, Yaeko Nakajima-Takagi, Atsushi Iwama, Arinobu Tojo
Journal: Blood (2020)
The intersection of genomics and big data with public health: Opportunities for precision public health
Authors: Muin J. Khoury, Gregory L. Armstrong, Rebecca E. Bunnell, Juliana Cyril, Michael F. Iademarco
Journal: PLoS Medicine (2020)

The field of precision public health (PPH) has emerged as a response to the increasing availability of genomics, biobanks, and other sources of big data in healthcare and public health.• The field has evolved starting with genomics to include multiple practical applications such as pathogen genomics that address population health.• PPH can expand understanding of health disparities, advance strategic public health science, and demonstrate the need for innovation and workforce development.• In the coronavirus disease 2019 (COVID-19) era, rapidly evolving scientific innovation can have a long-lasting impact on PPH beyond the pandemic.• Further developments in PPH will require global, national, and local leadership and stakeholder engagement.
Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia
Authors: Jayakumar Vadakekolathu, Tung On Yau, Sarah E. Church, Michael P. Rettig, Ibrahim Aldoss, Geoffrey L Uy, Norbert Vey, Ashkan Emadi, Peter H. Sayre, Roland B. Walter, Matthew C Foster, Martha L. Arellano, John E. Godwin, Matthew J. Wieduwilt, Michael T. Byrne, Laura C. Michaelis, Patrick J. Stiff, Matteo Giovanni Carrabba, Patrice Chevalier, Emmanuel Gyan, Christian Recher, Anjali S Advani, Martin Wermke, Harry P. Erba, Fabio Ciceri, Geert Huls, Mojca Jongen-Lavrencic, Farhad Ravandi, Antonio Curti, Max S. Topp, John Muth, Patrick Kaminker, Bob Lowenberg, Ivana Gojo, Leo Luznik, John F. DiPersio, Jan K Davidson-Moncada, Sergio Rutella
Journal: Blood (2020)
Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study
Authors: Zachary D. Epstein-Peterson, Connie Lee Batlevi, Philip Caron, Ahmet Dogan, Pamela Drullinsky, John Gerecitano, Audrey Hamilton, Paul A. Hamlin, Caleb Ho, Allison P. Jacob, Leana Laraque, Matthew J Matasar, Alison J. Moskowitz, Craig H. Moskowitz, Chelsea D Mullins, Colette Owens, Gilles Salles, Heiko Schöder, David J. Straus, Anas Younes, Andrew D Zelenetz, Anita Kumar
Journal: Blood (2020)
A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)
Authors: Urvi A Shah, Kelly Werner, Elizabet Tavitian, Sean Devlin, Sham Mailankody, Neha Korde, Malin Hultcrantz, Carlyn Tan, Sydney X. Lu, Eric L Smith, Francesco Maura, Dhwani Patel, Gunjan L. Shah, Oscar B Lahoud, Michael Scordo, Richard J Lin, Parastoo B. Dahi, Heather J Landau, David J. Chung, Hani Hassoun, Jonathan Landa, Bernard O'Malley, Christopher Barker, Taha Merghoub, Sergio A. Giralt, Ola Landgren, Joachim Yahalom, Alexander M. Lesokhin
Journal: Blood (2020)
Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Authors: Daniel Goldstein, Kyle A. Beckwith, Cecelia Miller, Ying Huang, Lynne V. Abruzzo, Seema A Bhat, David A. Bond, John C. Byrd, Michael R. Grever, Nyla A Heerema, Kerry A. Rogers, Amy S. Ruppert, Jennifer A. Woyach, Adam S. Kittai
Journal: Blood (2020)
Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease
Authors: Andrea Kristina Horst, Kingsley Gideon Kumashie, Katrin Neumann, Linda Diehl, Gisa Tiegs
Journal: Cellular and Molecular Immunology (2020)

The liver is an important immunological organ that controls systemic tolerance. The liver harbors professional and unconventional antigen-presenting cells that are crucial for tolerance induction and maintenance. Orchestrating the immune response in homeostasis depends on a healthy and well-toned immunological liver microenvironment, which is maintained by the crosstalk of liver-resident antigen-presenting cells and intrahepatic and liver-infiltrating leukocytes. In response to pathogens or autoantigens, tolerance is disrupted by unknown mechanisms. Intrahepatic parenchymal and nonparenchymal cells exhibit unique antigen-presenting properties. The presentation of microbial and endogenous lipid-, metabolite- and peptide-derived antigens from the gut via conventional and nonconventional mechanisms can educate intrahepatic immune cells and elicit effector responses or tolerance. Perturbation of this balance results in autoimmune liver diseases, such as autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. Although the exact etiologies of these autoimmune liver diseases are unknown, it is thought that the disruption of tolerance towards self-antigens and microbial metabolites and lipids, as well as alterations in bile acid composition, may result in changes in effector cell activation and polarization and may reduce or impair protective anti-inflammatory regulatory T and B cell responses. Additionally, the canonical and noncanonical transmission of antigens and antigen:MHC complexes via trogocytosis or extracellular vesicles between different (non) immune cells in the liver may play a role in the induction of hepatic inflammation and tolerance. Here, we summarize emerging aspects of antigen presentation, autoantibody production, and the application of novel therapeutic approaches in the characterization and treatment of autoimmune liver diseases.
Eltrombopag Specifically Expands Hematopoietic Multipotent Progenitors in Human Aplastic Anemia
Authors: Bruno Quintino Oliveira, Bárbara Santana, Luiz Fernando Bazzo Catto, Maria Florencia Tellechea, Priscila Santos Scheucher, Phillip Scheinberg, Rodrigo T. Calado
Journal: Blood (2020)
Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study
Authors: Georgia J McCaughan, Steven Tran, Simon Durrant, Simon J Harrison, James Morton, Noemi Horvath, Andrew Spencer, Ian H. Kerridge, Jeremy An Ke Er, Luani Barge, Adam Bryant, Robin J Filshie, Emily Choong, Hock Choong Lai, Campbell Tiley, Anthony K Mills, Andrew Butler, John Moore, Mark Hertzberg, Glen A Kennedy, P. Joy Ho, M Hasib Sidiqi, John Bashford, David Routledge, Kerry Taylor, Cindy H. Lee, Anna Kalff, Wei Xia, Nada Hamad
Journal: Blood (2020)
Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis
Authors: Jean-Jacques Kiladjian, John Mascarenhas, Rami S. Komrokji, Michele Cavo, Bruno Martino, Dietger Niederwieser, Andreas Reiter, Bart L. Scott, Maria R. Baer, Ronald Hoffman, Olatoyosi Odenike, Laurie Sherman, Souria Dougherty, Faye Feller, Fei Huang, Aleksandra Rizo, Libo Sun, Ying Wan, Alessandro M. Vannucchi
Journal: Blood (2020)
Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol
Authors: Lisa Eidenschink Brodersen, Chad A. Hudson, Todd A. Alonzo, Robert B. Gerbing, Laura Pardo, Amanda R. Leonti, Timothy P. Singleton, Fan-Chi Hsu, Loren L. Lott, Fangyan Dai, Keely Ghiradelli, E. Anders Kolb, Todd M. Cooper, Jessica A. Pollard, Michael R. Loken, Richard Aplenc, Soheil Meshinchi
Journal: Blood (2020)
SAT0071 Rofecoxib shows consistent efficacy in oa clinical trials, regardless of specific patient demographic and disease factors
Authors: LM DeTora, D Krupa, JA Bolognese, RS Sperling, EW Ehrich
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> Analyses were performed to demonstrate the generalizability of the efficacy of rofecoxib (MK-0966, VIOXXTM) in patients with different demographic or baseline disease characteristics, or with OA in nonsignal joints or multiple locations. <h3>Methods</h3> Data were combined for patients with OA of the knee or hip receiving placebo, 12.5 or 25 mg rofecoxib once daily in three 6-week placebo controlled trials, the only trials to date using all 3 treatments. Predefined analyses were performed after categorising patients according to baseline demographics (age, gender, height, weight BMI) and baseline disease characteristics (ARA functional class, joint tenderness, joint stiffness, WOMAC functional subscale, unilateral/bilateral joint involvement, number of joint groups involved). Three primary endpoints: Pain Walking on Flat Surface (WOMAC, 0- 100 mm VAS), Patient Global Assessment of Response to Therapy (0 to 4 point Likert Scale), and Investigator Global Assessment of Disease Status (0 to 4 point Likert Scale) were analysed. Efficacy treating OA in patients with 1, 2, 3, or 4, joint groups (among interphalangeal/first carpal-metacarpal joint, spine, hip or knee) affected was analysed for four end points, Patient and Investigator Global Assessments of Response to Therapy and of Disease Status (which provided data on overall aspects of OA, regardless of affected joint). Treatment by factor interactions were tested by ANOVA. <h3>Results</h3> Data from 1501 patients were included. For patients taking 12.5 or 25 mg rofecoxib, treatment effects were generally consistent across subgroups categorised by demographic factors: age (p = 0.08), gender (p = 0.06), race (p = 0.46), prior therapy (p = 0.19), weight (p = 0.10), BMI (p = 0.087) or disease characteristics: baseline joint tenderness (p = 0.17), WOMAC functional subscale (p = 0.52) ARA functional class I, II, or III (p = 0.49), duration of OA (p = 0.37), or primary study joint (p = 0.27). Greater efficacy was seen in patients with study joint swelling; however, the difference from those without study joint swelling was not clinically meaningful. No significant interactions were observed among patients with unilateral/bilateral involvement or 1, 2, 3, or 4, joint groups affected. <h3>Conclusion</h3> No specific factor predicted treatment effect in this study. This study was funded by a grant from Merck&amp; Co., Inc.
Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain
Authors: Lekha Mikkilineni, Elisabet E. Manasanch, Danielle Vanasse, Jennifer N. Brudno, Jennifer Mann, Richard Sherry, Stephanie L Goff, James C Yang, Norris Lam, Irina Maric, Maryalice Stetler-Stevenson, Hao-Wei Wang, Constance M. Yuan, David F. Stroncek, Steven L Highfill, Vicki Fellowes, Micaela Ganadan, Rashmika Patel, Steven A Rosenberg, James N. Kochenderfer
Journal: Blood (2020)
Abstract 373: Impacts of Harvesting Sites on Cardiac Extracellular Matrix Hydrogels Properties
Authors: Emily Mulvany, Sara McMahan, Jiazhu Xu, Narges Yazdani, Rebecca Willits, Jun Liao, Ge Zhang, Yi Hong
Journal: Circulation Research (2020)

Introduction: Cardiac extracellular matrix (cECM) hydrogel has been explored to treat myocardial infarction (MI). It possesses organ specific microenvironmental cues for resident cells and can be minimally invasive delivered into the heart using a transendocardial catheter. Recent clinical studies demonstrated the safety and feasibility of using cECM for treating MI patients. However, little is known about whether the region of cardiac tissue harvesting is critical for downstream applications. We performed in vitro studies to compare cECM hydrogels derived from porcine whole heart (WH), left ventricle (LV), and right ventricle (RV). Materials and Methods: Adult porcine hearts were obtained from a local USDA approved abattoir. The tissues were separated into 3 major categories: LV, RV, and WH tissues. Following our published protocol, tissues were decellularized and solubilized. The complete decellularization was confirmed by H&amp;E staining and DNA content measurement. Chemical composition was examined using SDS-PAGE electrophoresis as well as Collagen and GAGs measurements. The gelation time, SEM (hydrogel microstructures), and mechanical properties (storage and complex modulus) were studied. Human cardiomyocytes (CMs) and mesenchymal stem cells (MSCs) were separately seeded on the hydrogels to examine their responses. Cell viability and vascular differentiation of human MSCs were examined. Results and Discussion: The cECM from WH has more complex chemical composition compared with cECM from LV and RV. All three types of cECM hydrogels share many similarities in terms of their microstructure, gelation time and mechanical properties. WH-derived cECM hydrogels have larger variations in storage modulus (G’) and complex modulus (G*) compared with the other two types of cECM hydrogels. Both human CMs and MSCs could maintain high cell viability on all hydrogels. Regardless of harvesting sites, all cECM hydrogels have equivalent potency in directing vascular differentiation of seeded human MSCs. Conclusions: The cECM hydrogels from WH, LV and RV exhibited similarity in material properties and cell response in vitro . Future fabrication of cECM hydrogels from WH would increase the yield and decrease production cost.
SATB1 Regulates GATA1 Protein Expression in Early Hematopoiesis and Is Deregulated in Diamond Blackfan Anemia
Authors: Mark C Wilkes, Hee-Don Chae, Ethan Patrick Wentworth, Toshinobu Nishimura, Anupama Narla, Bertil Glader, Hiromitsu Nakauchi, Joanna Wysocka, Kathleen M. Sakamoto
Journal: Blood (2020)
Rarity of B-Cell Receptor Pathway Mutations in Progression-Free Patients With Chronic Lymphocytic Leukemia (CLL) During First-Line Versus Relapsed/Refractory (R/R) Treatment With Ibrutinib
Authors: Adrian Wiestner, Paolo Ghia, John C. Byrd, Inhye E Ahn, Carol Moreno, Susan M. O'Brien, Daniel Jones, Leo W. K. Cheung, Elizabeth Chong, Kevin Kwei, James P. Dean, Danelle F. James, Jennifer A. Woyach
Journal: Blood (2020)
Use of a plastic banded bag over the control body of the endoscope for COVID-19 prevention: a comment
Authors: Viroj Wiwanitkit
Journal: Endoscopy (2020)

See also: Use of a plastic banded bag over the control body of the endoscope as a splash guard to minimize the biological hazard during the COVID-19 outbreakEndoscopy 2020; 52(09): 818-818DOI: 10.1055/a-1167-2751
Creating a Variant Database for the American Society of Hematalogy By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies
Authors: Niroshan Nadarajah, Alex Wagner, Rafael Bejar, Mark Ewalt, Annette S. Kim, Michelle M. Le Beau, Xiaotu Ma, Manja Meggendorfer, Jamile M. Shammo, Gabriella Ryan, Alexa J. Siddon, David P. Steensma, Matthew J. Walter, Ahmet Zehir, Jinghui Zhang, Torsten Haferlach
Journal: Blood (2020)
Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study
Authors: Lauriane Clement-Filliatre, Lotfi Benboubker, Anne-Marie Stoppa, Philippe Rodon, Kamel Laribi, Laure Vincent, Philippe Collet, Valentine Richez, Anne Charvet-Rumpler, Hacene Zerazhi, Cyrille Hulin, Frederic Maloisel, Margaret Macro, Lionel Karlin, Nathalie Texier, Christos Chouaid, Xavier Leleu
Journal: Blood (2020)
Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation
Authors: Aimaz Afrough, Samer A. Srour, Qaiser Bashir, Neeraj Saini, Chitra Hosing, Uday R. Popat, Partow Kebriaei, Elizabeth J. Shpall, Ruby Delgado, Regan Murphy, Elisabet E. Manasanch, Hans C. Lee, Gregory P. Kaufman, Krina K. Patel, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Richard E. Champlin, Muzaffar H. Qazilbash
Journal: Blood (2020)
Assessing Dynamic Cerebral Autoregulation in Patients with Sickle Cell Disease Using Near-Infrared Spectroscopy and Paced Breathing
Authors: Sossena Wood, Abeselom Fanta, Atinuke Dosunmu-Ogunbi, Alexander Ruesch, Jude Jonassaint, Theodore Huppert, Enrico M Novelli, Jana Kainerstorfer
Journal: Blood (2020)